Drugs / Tomligisiran
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06537414 | Nov 2024 → May 2027 expected | chronic hepatitis B virus infection | GlaxoSmithKline | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-13 | GlaxoSmithKline | Results GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need gsk.com ↗
Simulation results show that added benefit of sequential daplusiran/tomligisiran followed by bepirovirsen versus bepirovirsen alone plus nucleos(t)ide analogs (NAs), could further increase functional cure rates in CHB. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-13 | GlaxoSmithKline | GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need gsk.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tomligisiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537414 ↗ |